Last reviewed · How we verify
HFO MDI
HFO MDI is a hydrofluoroolefin-based metered-dose inhaler formulation designed to deliver bronchodilator or corticosteroid therapy to the lungs with improved particle size distribution and lung deposition.
HFO MDI is a hydrofluoroolefin-based metered-dose inhaler formulation designed to deliver bronchodilator or corticosteroid therapy to the lungs with improved particle size distribution and lung deposition. Used for Asthma (maintenance and/or rescue therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | HFO MDI |
|---|---|
| Also known as | Propellant in MDI |
| Sponsor | AstraZeneca |
| Drug class | Inhaled bronchodilator or corticosteroid (formulation technology) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
HFO (hydrofluoroolefin) propellants replace older chlorofluorocarbon (CFC) propellants in metered-dose inhalers, offering better environmental safety and potentially improved aerosol characteristics. The MDI formulation optimizes drug particle size and distribution to enhance delivery to distal airways, improving therapeutic efficacy in obstructive airway diseases. This is a delivery technology platform rather than a novel molecular entity.
Approved indications
- Asthma (maintenance and/or rescue therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Throat irritation
Key clinical trials
- Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants (PHASE3)
- A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (PHASE3)
- Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma (PHASE3)
- A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PHASE3)
- Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (PHASE1)
- A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD (PHASE3)
- A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (PHASE1)
- A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |